drugset
drugset / Trial / NCT03662971

Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers

NCT03662971 ↗

Phase 1 Completed 42 enrolled Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

Phase I Clinical Trial to Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers.

Timeline

Start
2018-10-29
Primary completion
2018-12-04
Completion
2019-10-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Germinal peptide Peptide 0.0005 % Topical
Subject Germinal peptide Peptide 0.001 % Topical
Subject Germinal peptide Peptide 0.002 % Topical
Subject Germinal peptide Peptide 0.004 % Topical
Subject Germinal peptide Peptide 0.008 % Topical

Indications

corneal disorder